Ekspresija ciklooksigenaze-2 kod karcinoma grlića materice
Sažetak
Uvod/Cilj. Ciklooksigenaza (COX) ili prostaglandin H2 sintaza (PGHS) prvi je enzim koji katalizuje prva dva koraka biosinteze prostaglandina iz arahidonske kiseline. Cilj rada bio je da se ispita prisustvo i stepen ekspresije COX-2 u tkivu grlića materice ispitanica sa cervikalnim karcinomom i uporedi sa kontrolnom grupom bez cervikalne patologije. Metode. Istraživanjem je obuhvaćen patohistološki materijal uzet od 76 bolesnica podeljenih u dve grupe: kontrolna grupa – 30 bolesnica bez patohistoloških promena na grliću materice i grupa A – 46 bolesnica sa verifikovanim karcinomom grlića materice, FIGO stadijum IB-IIA. U obe grupe na patohistološkom materijalu izvršene su histološke i imunohistohemijske analize. Rezultati. U kontrolnoj grupi nije potvrđena ekspresija COX-2, a u grupi A jeste kod 26 (56,52%) bolesnica što je statistički značajna razlika u odnosu na kontrolnu grupu. Ispitivanjem ekspresije COX-2 i patohistoloških parametara, uočena je statistički značajna razlika u odnosu na postojanje limfocitne infiltracije (p = 0,0053). Ekspresija COX-2 bila je izraženija u tkivu bez limfocitne stromalne infiltracije (80% vs 20%). Zaključak. Ekspresija COX-2 bila je izraženija kod karcinoma grlića materice bez limfocitne stromalne infiltracije što navodi na zaključak o mogućem paradoksalnom efektu COX-2 na imunosupresiju u tumorskom tkivu. Nalaz češće ekspresije COX-2 u podgrupi sa lošijim prognostičkim patohistološkim parametrima u grupi A upućuju na značaj aktivnosti ekspresije COX-2 u procesu karcinogeneze karcinoma grlića materice i uticaja na njegovu progresiju.
Reference
Curado MP, Edwards B, Shin HR. Cancer Incidence in Five Continents. Lyon: IARC; 2007.
Pekmezović T. Cervical carcinoma: The significance of the problem. Proceedings of the Conference on Cervical Carcinoma – From the Diagnosis to Therapy. 2006 May 18−19; Geneva: ESGO Endorsed Meetings and Workshops; 2006. p. 1−3. (Serbian)
Dugandžija T, Miladinov-Mikov M. Epidemiological Characteris-tics of Cervical Cancer in Vojvodina 1993-2002. Proceeding of the International Conference on the Diagnostics and Man-agement on Breast Cancer and Cervical Cancer; Zagreb; 2006 March 6; Zagreb: Knjiga sažetaka 76; 2006.
Divvela AKC, Challa SR, Tagaram IK. Pathogenic role of Cyc-looxygenase -2 in cancer. J Healt Sci 2010; 56(5): 502−16.
Kim H, Youm H, Lee J, Min K, Chung J, Park C. Correlation be-tween cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003; 42(2): 163−70.
Sun Y, Tang XM, Half E, Kuo TM, Sinicrope FA. Cyclooxyge-nase-2 overexpression reduces apoptotic susceptibility by inhi-biting the cytochrome c-dependent apoptotic pathway in hu-man colon cancer cells. Cancer Res 2002; 62(21): 6323−8.
Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma andpancreatic intraepithelial neoplasia: an immunohistochemi-cal analysis with automated cellular imaging. Am J Clin Pathol 2002; 118(2): 194−201.
Liu JF, Jamieson G, Wu TC, Zhang SW, Wang QZ, Drew P. Cyc-looxygenase-2 expression in squamous cell carcinoma of the esophagus. Dis Esophagus 2006; 19(5): 350−4.
Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. In-creased expression of cyclooxygenase-2 protein in human gas-tric carcinoma. Clin Cancer Res 2000;6(2): 519−25.
Saukkonen K, Nieminen O, Rees B, Vilkki S, Härkönen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001; 7(7): 1923−31.
Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000; 6(6): 2424−30.
Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003; 63(10): 2347−50.
Ferrandina G, Ranelletti FO, Salutari V, Gessi M, Legge F, Zannoni GF, et al. Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions. Gynecol Oncol 2004; 92(2): 537−44.
Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylino-sitol 3-kinase/Akt pathway. J Biol Chem 2001; 276(52): 48997−9002.
Cao Y, Pearman AT, Zimmerman GA, Mcintyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97(21): 11280−5.
Dai Y, Zhang X, Peng Y, Wang Z. The expression of cycloox-ygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 2005; 97(1): 96−103.
Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the uri-nary bladder. Cancer Res 1999; 59(22): 5647−50.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on day/month/year.
Dixon DA. Regulation of COX-2 expression in human can-cers. In: Bertino RJ, Dannenberg AJ, du Bois RN, editors. COX-2 a new target for cancer prevention and treatment. Progress in experimental tumor research. Basel: Karger; 2003. p. 52−72.
Hartmann LC, Lingle W, Frost MH, Shaun D, Maloney RA, Vierkant V, et. al. COX-2 expression in atypia: correlation with breast cancer risk. 97th Annual Meeting. 2006 March 31- April 5; Washington, DC: American Association for Cancer Research; 2006.
Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. En-hanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Ga-stroenterol 2001; 36(8): 865−9.
Sudbø J, Ristimäki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2003; 39(5): 497−505.
Oku S, Higashi M, Imazono Y, Sueyoshi K, Enokida H, Kubo H, et al. Overexpression of cyclooxygenase-2 in high-grade human transitional cell carcinoma of the upper urinary tract. BJU Int 2003; 91(1): 109−14.
Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006; 94(2): 253−8.
Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S, et al. Overexpression of cyclooxygenase-2 is asso-ciated with a favorable prognostic phenotype in breast carci-noma. Pathobiology 2005; 72(5): 241−9.
Nasir A, Kaiser HE, Boulware D, Hakam A, Zhao H, Yeatman T, et al. Cyclooxygenase-2 expression in right- and left-sided co-lon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer 2004; 3(4): 243−7.
Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, et al. Co-expression of VEGF-C and COX-2 in human colo-rectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006; 49(3): 393−8.
Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6(12): 4739−44.
Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59(5): 987−90.
Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Cancer and Its Expression Is Regulated by the Mes-senger RNA Stability Factor HuR. Clin Cancer Res 2005; 11(20): 7362−8.
Li M, Qi S, Wang Y, Feng S, Zhang B, Wang R. Expression and clinical significance of vascular endothelial growth factor, cyc-looxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch Gynecol Obstet 2005; 272(1): 48−52.
Denkert C, bel Ko ¨M, Pest S, Koch I, Berger S, Schwabe M, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160(3): 893−903.
Chou Y, Chen Y, Lai C, Wang P, Yuan C. Cyclooxygenase-2 ex-pression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis. Eur J Obstet Gynecol Reprod Biol 2006; 124(1): 101−5.
Nasir A, Boulware D, Kaiser HE, Lancaster JM, Coppola D, Smith PV, et al.. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo 2007; 21(1): 35−43.
Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002; 95(4): 801−7.
Nofech-Mozes S, Kupets R, Rasty G, Ismiil N, Covens A, Khalifa MA. Cyclooxygenase 2 (COX-2) Immunostaining Does Not Correlate With the Degree of Vulvar Neoplasia. J Obstet Gy-naecol Can 2006; 28(4): 290−4.
Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: A review. Gynecol Oncol 2008; 109(1): 140−5.
Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 onco-proteins: evidence of a corepressor/coactivator exchange. Cancer Res 2007; 67(8): 3976−85.
Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol 2004; 92(2): 596−602.
Kim JY, Lim SJ, Park K, Lee C, Kim J. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005; 97(2): 337−41.
Dursun P, Yuce K, Usubutun A, Ayhan A. Cyclooxygenase-2 ex-pression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopatho-logic variables. Int J Gynecol Cancer 2007; 17(1): 164−73.
Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Ruangvejvo-rachai P, Thorner PS, et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis. Gynecol Oncol 2009; 112(1): 241−7.
Luo C, Zhu R, Wang H, Lu Y. Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance. Zhonghua Zhong Liu Za Zhi 2007; 29(7): 526−30. (Chinese)
Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrun-gruanglert W, Tresukosol D. Prevalence and prognostic signific-ance of COX-2 expression in stage IB cervical cancer. Gyne-col Oncol 2006; 100(3): 556−60.
Huang M, Chen Q, Xiao J, Liu C, Zhao X. Prognostic significance of cyclooxygenase-2 in cervical cancer: A meta-analysis. Int J Cancer 2013; 132(2): 363−73.
Kim J, Li S, Kim J, Yeo S, Kim K, Cho M. Cyclooxygenase-2 ex-pression as a predictor of para-aortic lymph node recurrence in uterine cervical cancer. Int J Radiat Oncol Biol Phys 2008; 70(5): 1516−21.
Klimek M, Urbański K, Kojs Z, Karolewski K, Pudełek J, Blecharz P. Role of cyclooxygenase-2 in cervical cancer. Arch Med Sci 2009; 5(3): 303−7.
Staveley-O'Carroll K, Sotomayor E, Montgomery J. Induction of an-tigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95(3): 1178−83.